Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report

Monitor this Company

SCOTTSDALE, Ariz., Dec. 4 // -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.

    In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.

    "Recent changes to the American Diabetes Association guidelines highlight the diabetic's increased risk for coronary artery disease (CAD)," according to MedPredict's President Jeff Berk. "In light of these guidelines, our Panel provides insight into unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."


    Also discussed:

    -- Incretins will dominate new launches for HbA1c lowering drugs for the

     next few years. The Panel discusses the significance of targeting

     DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.

     Strengths and weaknesses of new monotherapies and combination

     approaches are discussed.

    -- These new orals and parenterals will put pressure on established

     products, including metformin, sulfonylureas and TZDs. The Panel

     offers insight into how each fits into the diabetes / CAD paradigm.

    -- The Panel describes why Exubera has failed commercially, and

     benchmarks next-generation insulins.

    -- While still very early in development, the Panel shared key insights

     about the future for inhibition of SGLT.

    Key products mentioned in this report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), Exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo Nordisk/Aradigm), Oral-lyn (Generex/Lilly), buccal insulin (GSK).

    This report can be purchased by contacting MedPredict. Members of the media may request an interview.

    About MedPredict

    MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
Monitor this Company :
You will receive an email alert whenever there is a news item concerning this company.
Name Your Company
Email Address Position/Role


2001 - 2016 Lexdon Business Library
About TrustBase
Privacy Policy